BridgeBio Pharma vs Ionis Pharmaceuticals
BBIO and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and IONS compare
BridgeBio Pharma is the larger company, worth 3.4 times as much as Ionis Pharmaceuticals ($15.2B against $4.5B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus −0.71% for Ionis Pharmaceuticals).
Ionis Pharmaceuticals scores higher on the StockData Score (4 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | IONS |
|---|---|---|
| Size and price | ||
| Market cap | $15.2B | $4.5B |
| Share price | $78.17 | $27.31 |
| Change, 1 year | 17.4% | −62.3% |
| Change, 5 years | 83.3% | −14.6% |
| Beta (5Y) | 1.11 | 0.65 |
| Employees | 834 | 1,402 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 16.1× | 4.7× (better) |
| P/B | – | 11.5× |
| FCF yield | −2.4% (better) | −13.6% |
| Fair value | – | $28.15 |
| Margin of safety | – | 3.0% |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | −0.71% |
| Revenue growth, 5Y average | 127% (better) | 5.3% |
| Profitability | ||
| Gross margin | 94.3% | 98.2% (better) |
| Operating margin | −38.5% (better) | −58.8% |
| Net margin | – | −56.9% |
| FCF margin | −39.1% (better) | −64.2% |
| Return on equity | – | −108% |
| Financial health | ||
| Interest coverage | −7.1× (better) | −29.4× |
| Current ratio | 2.09 | 5.43 (better) |
| Altman Z-score | 0.15 (better) | 0.15 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | – |
| Shareholder yield | 1.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.4% | 108% |
| Held by insiders | 35.6% | 0.80% |
| Insider net buying, 12 months | −$84.8M (better) | −$114M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 16.6% | 12.8% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- IONS stock overview
- IONS income statement
- IONS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.